Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures.

Kevin RC, Kovach AL, Lefever TW, Gamage TF, Wiley JL, McGregor IS, Thomas BF.

Forensic Toxicol. 2019 Jan;37(1):17-26. doi: 10.1007/s11419-018-0430-0. Epub 2018 Jun 28.

PMID:
30705707
2.

Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats.

Barrus DG, Lefever TW, Wiley JL.

Neuropharmacology. 2018 Jul 15;137:133-140. doi: 10.1016/j.neuropharm.2018.04.018. Epub 2018 May 3.

PMID:
29758385
3.

Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.

Amato GS, Manke A, Harris DL, Wiethe RW, Vasukuttan V, Snyder RW, Lefever TW, Cortes R, Zhang Y, Wang S, Runyon SP, Maitra R.

J Med Chem. 2018 May 24;61(10):4370-4385. doi: 10.1021/acs.jmedchem.7b01820. Epub 2018 May 10.

PMID:
29688015
4.

Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2018 May;365(2):437-446. doi: 10.1124/jpet.117.246983. Epub 2018 Mar 16.

PMID:
29549157
5.

Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.

Marusich JA, Wiley JL, Lefever TW, Patel PR, Thomas BF.

Neuropharmacology. 2018 May 15;134(Pt A):73-81. doi: 10.1016/j.neuropharm.2017.10.041. Epub 2017 Nov 4.

PMID:
29113898
6.

Tobacco's minor alkaloids: Effects on place conditioning and nucleus accumbens dopamine release in adult and adolescent rats.

Marusich JA, Darna M, Wilson AG, Denehy ED, Ebben A, Deaciuc AG, Dwoskin LP, Bardo MT, Lefever TW, Wiley JL, Reissig CJ, Jackson KJ.

Eur J Pharmacol. 2017 Nov 5;814:196-206. doi: 10.1016/j.ejphar.2017.08.029. Epub 2017 Aug 26.

PMID:
28844873
7.

Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Gamage TF, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Drug Test Anal. 2018 Jan;10(1):137-147. doi: 10.1002/dta.2262. Epub 2017 Sep 28.

8.

In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Forensic Toxicol. 2017;35(2):333-347. doi: 10.1007/s11419-017-0361-1. Epub 2017 Mar 10.

9.

The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Gamage TF, Farquhar CE, Lefever TW, Thomas BF, Nguyen T, Zhang Y, Wiley JL.

Neuropharmacology. 2017 Oct;125:365-375. doi: 10.1016/j.neuropharm.2017.08.008. Epub 2017 Aug 10.

10.

Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice.

Lefever TW, Marusich JA, Thomas BF, Barrus DG, Peiper NC, Kevin RC, Wiley JL.

Subst Abuse. 2017 Apr 7;11:1178221817701739. doi: 10.1177/1178221817701739. eCollection 2017.

11.

Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Lefever TW, Lee YO, Kovach AL, Silinski MA, Marusich JA, Thomas BF, Wiley JL.

Drug Alcohol Depend. 2017 Mar 1;172:80-87. doi: 10.1016/j.drugalcdep.2016.12.004. Epub 2017 Jan 18.

12.

Comparison of the discriminative stimulus and response rate effects of Δ9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats.

Wiley JL, Lefever TW, Marusich JA, Craft RM.

Drug Alcohol Depend. 2017 Mar 1;172:51-59. doi: 10.1016/j.drugalcdep.2016.11.035. Epub 2017 Jan 11.

13.

Tasty THC: Promises and Challenges of Cannabis Edibles.

Barrus DG, Capogrossi KL, Cates SC, Gourdet CK, Peiper NC, Novak SP, Lefever TW, Wiley JL.

Methods Rep RTI Press. 2016 Nov;2016. doi: 10.3768/rtipress.2016.op.0035.1611.

14.

Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Thomas BF, Lefever TW, Cortes RA, Grabenauer M, Kovach AL, Cox AO, Patel PR, Pollard GT, Marusich JA, Kevin RC, Gamage TF, Wiley JL.

J Pharmacol Exp Ther. 2017 Apr;361(1):162-171. doi: 10.1124/jpet.116.238717. Epub 2017 Jan 13. Erratum in: J Pharmacol Exp Ther. 2017 May;361(2):245.

15.

Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Wiley JL, Lefever TW, Marusich JA, Grabenauer M, Moore KN, Huffman JW, Thomas BF.

Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.

16.

Just add water: cannabinoid discrimination in a water T-maze with FAAH(-/-) and FAAH(+/+) mice.

Wiley JL, Lefever TW, Pulley NS, Marusich JA, Cravatt BF, Lichtman AH.

Behav Pharmacol. 2016 Aug;27(5):479-84. doi: 10.1097/FBP.0000000000000228.

17.

Pharmacological effects of methamphetamine and alpha-PVP vapor and injection.

Marusich JA, Lefever TW, Blough BE, Thomas BF, Wiley JL.

Neurotoxicology. 2016 Jul;55:83-91. doi: 10.1016/j.neuro.2016.05.015. Epub 2016 May 26.

18.

The impact of gonadal hormones on cannabinoid dependence.

Marusich JA, Craft RM, Lefever TW, Wiley JL.

Exp Clin Psychopharmacol. 2015 Aug;23(4):206-16. doi: 10.1037/pha0000027.

19.

AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.

Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF.

J Pharmacol Exp Ther. 2015 Sep;354(3):328-39. doi: 10.1124/jpet.115.225326. Epub 2015 Jun 23.

20.

Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats.

Wiley JL, Lefever TW, Cortes RA, Marusich JA.

Pharmacol Biochem Behav. 2014 Sep;124:123-8. doi: 10.1016/j.pbb.2014.05.016. Epub 2014 Jun 2.

21.

Evaluation of sex differences in cannabinoid dependence.

Marusich JA, Lefever TW, Antonazzo KR, Craft RM, Wiley JL.

Drug Alcohol Depend. 2014 Apr 1;137:20-8. doi: 10.1016/j.drugalcdep.2014.01.019. Epub 2014 Feb 12.

22.

Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Lefever TW, Marusich JA, Antonazzo KR, Wiley JL.

Pharmacol Biochem Behav. 2014 Mar;118:30-5. doi: 10.1016/j.pbb.2014.01.002. Epub 2014 Jan 9.

23.

Prediction and Prevention of Prescription Drug Abuse: Role of Preclinical Assessment of Substance Abuse Liability.

Marusich JA, Lefever TW, Novak SP, Blough BE, Wiley JL.

Methods Rep RTI Press. 2013 Jul:1-14.

24.

Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF.

Neuropharmacology. 2013 Dec;75:145-54. doi: 10.1016/j.neuropharm.2013.07.022. Epub 2013 Aug 2.

25.

Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats.

Ward SJ, Lefever TW, Rawls SM, Whiteside GT, Walker EA.

Psychopharmacology (Berl). 2009 Sep;206(1):155-65. doi: 10.1007/s00213-009-1592-6. Epub 2009 Jul 3.

PMID:
19575185
26.

Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice.

Ward SJ, Lefever TW, Jackson C, Tallarida RJ, Walker EA.

J Pharmacol Exp Ther. 2008 May;325(2):567-76. doi: 10.1124/jpet.107.131771. Epub 2008 Feb 6.

PMID:
18256173
27.

Intraparaventricular neuropeptide Y and ghrelin induce learned behaviors that report food deprivation in rats.

Jewett DC, Lefever TW, Flashinski DP, Koffarnus MN, Cameron CR, Hehli DJ, Grace MK, Levine AS.

Neuroreport. 2006 May 15;17(7):733-7.

PMID:
16641678

Supplemental Content

Loading ...
Support Center